Advertisement

Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation

  • Fernanda CrunfliEmail author
  • Talita A. Vrechi
  • Andressa P. Costa
  • Andréa S. Torrão
Original Article

Abstract

The cannabinoid system has the ability to modulate cellular and molecular mechanisms, including excitotoxicity, oxidative stress, apoptosis, and inflammation, acting as a neuroprotective agent, by its relationship with signaling pathways associated to the control of cell proliferation, differentiation, and survival. Recent reports have raised new perspectives on the possible role of cannabinoid system in neurodegenerative diseases like Alzheimer disease’s (AD). AD is a neurodegenerative disorder characterized by the presence of amyloid plaques, neurofibrillary tangles, neuronal death, and progressive cognitive loss, which could be caused by energy metabolism impairment, changes in insulin signaling, chronic oxidative stress, neuroinflammation, Tau hyperphosphorylation, and Aβ deposition in the brain. Thus, we investigated the presumptive protective effect of the cannabinoid type 1 (CB1)-selective receptor agonist arachidonyl-2′-chloroethylamide (ACEA) against streptozotocin (STZ) exposure stimuli in an in vitro neuronal model (Neuro-2a neuroblastoma cells) and in vivo model (intracerebroventricular STZ injection), experimental models of sporadic AD. Our results demonstrated that ACEA treatment reversed cognitive impairment and increased activity of Akt and ERK triggered by STZ, and increased IR expression and increased the anti-apoptotic proteins levels, Bcl-2. In the in vitro model, ACEA was able to rescue cells from STZ-triggered death and modulated the NO release by STZ. Our study has demonstrated a participation of the cannabinoid system in cellular survival, involving the CB1 receptor, which occurs by positive regulation of the anti-apoptotic proteins, suggesting the participation of this system in neurodegenerative processes. Our data suggest that the cannabinoid system is an interesting therapeutic target for the treatment of neurodegenerative diseases.

Keywords

Agonist CB1 ACEA Neuroprotection Streptozotocin Alzheimer’s disease Neurodegeneration 

Notes

Acknowledgments

Authors wish to thank the professor Dr. Julián Romero (Universidad Francisco de Vitoria, Madrid, Spain) for critical comments and his technical support during the process. We also thank to Dr. Maria Assunción de la Barreda Manso for her opinion and critical comments.

Financial Support

This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo-FAPESP (grant number 2014/06372-0). T.A.V. (1279985) and F.C. (1233360) are recipients of Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) fellowships.

Author Contributions

F.C. designed the experiments, collected, and analyzed the data and wrote the paper; T.A.V. and A.P.C. collected, analyzed, and discussed the data; A.S.T. designed the experiments, discussed the data, wrote, edited, and commented on the manuscript. All authors approved the final version of the manuscript.

Compliance with Ethical Standards

The experimental protocol was evaluated and approved by the “Ethics Committee for Animal use” of the Institute of Biomedical Sciences, University of São Paulo (Protocol no. 33/55/02) following the Brazilian Federal Law (no. 11794; 10/08/2008). All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:197–201.  https://doi.org/10.1016/S0304-3940(01)02065-1 CrossRefPubMedGoogle Scholar
  2. Agrawal R, Tyagi E, Shukla R, Nath C (2011) Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur Neuropsychopharmacol 21:261–273.  https://doi.org/10.1016/j.euroneuro.2010.11.009 CrossRefPubMedGoogle Scholar
  3. Ahmad F, Nidadavolu P, Durgadoss L, Ravindranath V (2014) Critical cysteines in Akt1 regulate its activity and proteasomal degradation: implications for neurodegenerative diseases. Free Radic Biol Med 74:118–128.  https://doi.org/10.1016/j.freeradbiomed.2014.06.004 CrossRefPubMedGoogle Scholar
  4. Aso E, Ferrer I (2014) Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol 5:1–11.  https://doi.org/10.3389/fphar.2014.00037 CrossRefGoogle Scholar
  5. Aso E, Palomer E, Juvés S, Maldonado R, Muñoz FJ, Ferrer I (2012) CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. J Alzheimers Dis 30:439–459.  https://doi.org/10.3233/JAD-2012-111862 CrossRefPubMedGoogle Scholar
  6. Barzegar S, Komaki A, Shahidi S, Sarihi A, Mirazi N, Salehi I (2015) Effects of cannabinoid and glutamate receptor antagonists and their interactions on learning and memory in male rats. Pharmacol Biochem Behav 131:87–90.  https://doi.org/10.1016/j.pbb.2015.02.005 CrossRefPubMedGoogle Scholar
  7. Batinga H, Zúñiga-Hertz JP, Torrão AS (2016) Cannabinoid receptor ligands prevent dopaminergic neurons death induced by neurotoxic, inflammatory and oxidative stimuli in vitro. J Biomed Sci 5:1–16CrossRefGoogle Scholar
  8. Bedse G, Di Domenico F, Serviddio G, Cassano T (2015) Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front Neurosci 9:1–13.  https://doi.org/10.3389/fnins.2015.00204 CrossRefGoogle Scholar
  9. Benito C, Núñez E, Pazos MR, Tolón RM, Romero J (2007) The endocannabinoid system and Alzheimer’s disease. Mol Neurobiol 36:75–81.  https://doi.org/10.1007/s12035-007-8006-8 CrossRefPubMedGoogle Scholar
  10. Blázquez C, Chiarlone A, Bellocchio L, Resel E, Pruunsild P, García-Rincón D, Sendtner M, Timmusk T, Lutz B, Galve-Roperh I, Guzmán M (2015) The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ 22:1618–1629.  https://doi.org/10.1038/cdd.2015.11 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Café-Mendes CC, Ferro ES, Torrão AS, Crunfli F, Rioli V, Schmitt A, Falkai P, Britto LR, Turck CW, Martins-de-Souza D (2017) Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. J Proteome 151:97–105.  https://doi.org/10.1016/j.jprot.2016.05.025 CrossRefGoogle Scholar
  12. Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C (2012) Cannabinoids: a new hope for breast cancer therapy? Cancer Treat Rev 38:911–918.  https://doi.org/10.1016/j.ctrv.2012.06.005 CrossRefPubMedGoogle Scholar
  13. Calderón FH, Bonnefont A, Muñoz FJ, Fernández V, Videla LA, Inestrosa NC (1999) PC12 and neuro 2ª cells have diferente susceptibilities to acetylcholinesterase-amyloid complexes, amyloid 25-35 fragment, glutamate, and hydrogen peroxide. J Neurosci Res 56:620–631.  https://doi.org/10.1002/(SICI)1097-4547(19990615)56:6<620::AID-JNR8>3.0.CO;2-F CrossRefPubMedGoogle Scholar
  14. Caltana LR, Heimrich B, Brusco A (2015) Further evidence for the neuroplastic role of cannabinoids: a study in organotypic hippocampal slice cultures. J Mol Neurosci 56:773–781.  https://doi.org/10.1007/s12031-015-0499-4 CrossRefPubMedGoogle Scholar
  15. Carney ST, Lloyd ML, MacKinnon SE, Newton DC, Jones JD, Howlett AC, Norford DC (2009) Cannabinoid regulation of nitric oxide synthase i (nNOS) in neuronal cells. J NeuroImmune Pharmacol 4:338–349.  https://doi.org/10.1007/s11481-009-9153-7 CrossRefPubMedPubMedCentralGoogle Scholar
  16. Coffer PJ, Geijsen N, M’rabet L, Schweizer RC, Maikoe T, Raaijmakers JAM, Lammers JWJ, Koenderman L (1998) Comparison of the roles of mitogen-activated protein kinase kinase and phosphatidylinositol 3-kinase signal transduction in neutrophil effector function. Biochem J 329(Pt1):121–130CrossRefGoogle Scholar
  17. Colucci-D’Amato L, Perrone-Capano C, Di Porzio U (2003) Chronic activation of ERK and neurodegenerative diseases. BioEssays 25:1085–1095.  https://doi.org/10.1002/bies.10355 CrossRefPubMedGoogle Scholar
  18. Crunfli F, Mazucanti CH, De Moraes RCM, Costa AP, Rodrigues AC, Scavone C, Torrão AS (2018) NO-dependent Akt inactivation by S-nitrosylation as a possible mechanism of STZ-induced neuronal insulin resistance. J Alzheimers Dis 65:1427–1443.  https://doi.org/10.3233/JAD-180284 CrossRefPubMedGoogle Scholar
  19. De Felice F, Ferreira S (2002) β-Amyloid production, aggergation, and clearance as targets for therapy in Alzheimer’s disease. Cell Mol Neurobiol 22:545–563CrossRefGoogle Scholar
  20. De Felice FG, Lourenco MV, Ferreira ST (2014) How does brain insulin resistance develop in Alzheimer’s disease? Alzheimers Dement 10:S26–S32.  https://doi.org/10.1016/j.jalz.2013.12.004 CrossRefPubMedGoogle Scholar
  21. De La Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 88:548–559.  https://doi.org/10.1016/j.bcp.2013.12.012 CrossRefPubMedGoogle Scholar
  22. De la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 7:45–61.  https://doi.org/10.3233/JAD-2005-7106 CrossRefPubMedGoogle Scholar
  23. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371–2382 23/6/2371 [pii] CrossRefGoogle Scholar
  24. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, Piscitelli F, Westerbacka J, Soro-Paavonen A, Matias I, Van Gaal L, Taskinen MR (2009) Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 161:715–722.  https://doi.org/10.1530/EJE-09-0643 CrossRefPubMedGoogle Scholar
  25. Di Marzo V, Stella N, Zimmer A (2015) Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 16(1):30–42.  https://doi.org/10.1038/nrn3876 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Downward J (1999) How BAD phosphorylation is good for survival. Nat Cell Biol 1:E33–E35.  https://doi.org/10.1038/10026 CrossRefPubMedGoogle Scholar
  27. El-Mir MY, Detaille D, R-Villanueva G, Esteban MD, Guigas B, Attia S, Fontaine E, Almeida A, Leverve X (2008) Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34:77–87.  https://doi.org/10.1007/s12031-007-9002-1 CrossRefPubMedGoogle Scholar
  28. Ellert-Miklaszewska A, Kaminska B, Konarska L (2005) Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17:25–37.  https://doi.org/10.1016/j.cellsig.2004.05.011 CrossRefPubMedGoogle Scholar
  29. Esposito G, De Filippis D, Steardo L, Scuderi C, Savani C, Cuomoa V, Iuvone T (2006) CB1 receptor selective activation inhibits β-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett 404:342–346.  https://doi.org/10.1016/j.neulet.2006.06.012 CrossRefPubMedGoogle Scholar
  30. Esposito G, Ligresti A, Izzo AA, Bisogno T, Ruvo M, Di Rosa M, Di Marzo V, Iuvone T (2002) The endocannabinoid system protects rat glioma cells against HIV-1 tat protein-induced cytotoxicity: mechanism and regulation. J Biol Chem 277:50348–50354.  https://doi.org/10.1074/jbc.M207170200 CrossRefPubMedGoogle Scholar
  31. Fernández-López D, Martínez-Orgado J, Nuñez E, Romero J, Lorenzo P, Moro MA, Lizasoain I (2006) Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 60:169–173.  https://doi.org/10.1203/01.pdr.0000228839.00122.6c CrossRefPubMedGoogle Scholar
  32. Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA (2008) Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 286:S91–S96.  https://doi.org/10.1016/j.mce.2008.01.001 CrossRefPubMedGoogle Scholar
  33. Ferreiro E, Eufrásio A, Pereira C, Oliveira CR, Rego AC (2007) Bcl-2 overexpression protects against amyloid-beta and prion toxicity in GT1-7 neural cells. J Alzheimers Dis 12:223–228.  https://doi.org/10.3233/JAD-2007-12303 CrossRefPubMedGoogle Scholar
  34. Ferrer I, Blanco R, Carmona M, Puig B (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons. J Neural Transm 108:1397–1415.  https://doi.org/10.1007/s007020100016 CrossRefPubMedGoogle Scholar
  35. Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S, Zöchling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 105:423–438.  https://doi.org/10.1007/s007020050068 CrossRefPubMedGoogle Scholar
  36. Gilbert GL, Kim HJ, Waataja JJ, Thayer S (2007) Δ9-Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 1128:61–69.  https://doi.org/10.1016/j.brainres.2006.03.011 CrossRefPubMedGoogle Scholar
  37. Goodman J, Packard MG (2015) The influence of cannabinoids on learning and memory processes of the dorsal striatum. Neurobiol Learn Mem 125:1–14.  https://doi.org/10.1016/j.nlm.2015.06.008 CrossRefPubMedGoogle Scholar
  38. Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S (2006) Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136:2715–2721CrossRefGoogle Scholar
  39. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126:131–138.  https://doi.org/10.1016/0003-2697(82)90118-X CrossRefPubMedGoogle Scholar
  40. Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 60:910–920.  https://doi.org/10.1016/j.neuropharm.2011.01.033 CrossRefPubMedGoogle Scholar
  41. Harvey BS, Ohlsson KS, Mååg JLV, Musgrave IF, Smid SD (2012) Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology 33:138–146.  https://doi.org/10.1016/j.neuro.2011.12.015 CrossRefPubMedGoogle Scholar
  42. Hashimotodani Y, Ohno-Shosaku T, Kano M (2007) Endocannabinoids and synaptic function in the CNS. Neuroscientist 13:127–137.  https://doi.org/10.1177/1073858406296716 CrossRefPubMedGoogle Scholar
  43. Henneberg N, Hoyer S (1995) Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr 21:63–74.  https://doi.org/10.1016/0167-4943(95)00646-3 CrossRefPubMedGoogle Scholar
  44. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289:1427–1433PubMedGoogle Scholar
  45. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 104:1433–1439.  https://doi.org/10.1111/j.1471-4159.2007.05194.x CrossRefPubMedPubMedCentralGoogle Scholar
  46. Hoyer S (2002) The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109:341–360.  https://doi.org/10.1007/s007020200028 CrossRefPubMedGoogle Scholar
  47. Hoyer S, Muller D, Plaschke K (1994) Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl 44:259–268PubMedGoogle Scholar
  48. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, Uchida T, Imahori K (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 325:167–172CrossRefGoogle Scholar
  49. Jordan JD, He JC, Eungdamrong NJ, Gomes I, Ali W, Nguyen T, Bivona TG, Philips MR, Devi LA, Iyengar R (2005) Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through Gαo/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem 280:11413–11421.  https://doi.org/10.1074/jbc.M411521200 CrossRefPubMedGoogle Scholar
  50. Kamat PK, Kalani A, Rai S, Tota SK, Kumar A, Ahmad AS (2016) Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: a therapeutic intervention for treatment of sporadic Alzheimer’s disease (sAD)-like pathology. Mol Neurobiol 53:4548–4562.  https://doi.org/10.1007/s12035-015-9384-y CrossRefPubMedGoogle Scholar
  51. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733–736.  https://doi.org/10.1038/325733a0 CrossRefPubMedGoogle Scholar
  52. Kar S, Slowikowski SPM, Westaway D, Mount HTJ (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29:427–441PubMedPubMedCentralGoogle Scholar
  53. Karanian DA (2005) Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 25:7813–7820.  https://doi.org/10.1523/JNEUROSCI.2347-05.2005 CrossRefPubMedGoogle Scholar
  54. Kokona D, Thermos K (2015) Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: involvement of PI3K/Akt and MEK/ERK signaling pathways. Exp Eye Res 136:45–58.  https://doi.org/10.1016/j.exer.2015.05.007 CrossRefPubMedGoogle Scholar
  55. Kosik K, Joachim C, Selkoe D (1987) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Alzheimer Dis Assoc Disord 1:203.  https://doi.org/10.1097/00002093-198701030-00022 CrossRefGoogle Scholar
  56. Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, Pisanti S, Santoro A, Caruso MG, Bifulco M (2010) Inhibition of 3-hydroxy-3-methylglutarylcoenzyme a reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. Endocr Relat Cancer 17:495–503.  https://doi.org/10.1677/ERC-10-0009 CrossRefPubMedGoogle Scholar
  57. Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long- term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208.  https://doi.org/10.1037//0735-7044.112.5.1199 CrossRefPubMedGoogle Scholar
  58. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, De la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 9:13–33.  https://doi.org/10.3233/JAD-2006-9102 CrossRefPubMedGoogle Scholar
  59. Lipina C, Hundal HS (2017) The endocannabinoid system: “NO” longer anonymous in the control of nitrergic signalling? J Mol Cell Biol 9:91–103.  https://doi.org/10.1093/jmcb/mjx008 CrossRefPubMedPubMedCentralGoogle Scholar
  60. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448–456.  https://doi.org/10.1046/j.0022-3042.2001.00716.x CrossRefPubMedGoogle Scholar
  61. Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9:8.  https://doi.org/10.1186/1742-2094-9-8 CrossRefPubMedPubMedCentralGoogle Scholar
  62. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564.  https://doi.org/10.1038/346561a0 CrossRefPubMedGoogle Scholar
  63. Milton NGN (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide. Neurosci Lett 332:127–130.  https://doi.org/10.1016/S0304-3940(02)00936-9 CrossRefPubMedGoogle Scholar
  64. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63.  https://doi.org/10.1016/0022-1759(83)90303-4 CrossRefPubMedGoogle Scholar
  65. Mumby DG (2002) Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts. Learn Mem 9:49–57.  https://doi.org/10.1101/lm.41302 CrossRefPubMedPubMedCentralGoogle Scholar
  66. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65.  https://doi.org/10.1038/365061a0 CrossRefPubMedGoogle Scholar
  67. Nicolas O, Gavin R, Braun N, Ureña JM, Fontana X, Soriano E, Aguzzi A, del Río JA (2007) Bcl-2 overexpression delays caspase-3 activation and rescues cerebellar degeneration in prion-deficient mice that overexpress amino-terminally truncated prion. FASEB J 21:3107–3117.  https://doi.org/10.1096/fj.06-7827com CrossRefPubMedGoogle Scholar
  68. Nitsch R, Hoyer S (1991) Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 128:199–202.  https://doi.org/10.1016/0304-3940(91)90260-Z CrossRefPubMedGoogle Scholar
  69. Numajiri N, Takasawa K, Nishiya T, Tanaka H, Ohno K, Hayakawa W, Asada M, Matsuda H, Azumi K, Kamata H, Nakamura T, Hara H, Minami M, Lipton SA, Uehara T (2011) On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc Natl Acad Sci U S A 108:10349–10354.  https://doi.org/10.1073/pnas.1103503108 CrossRefPubMedPubMedCentralGoogle Scholar
  70. Osmanovic Barilar J, Knezovic A, Grünblatt E, Riederer P, Salkovic-Petrisic M (2015) Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease. J Neural Transm 122:565–576.  https://doi.org/10.1007/s00702-014-1323-y CrossRefPubMedGoogle Scholar
  71. Paradis E, Koutroumanis M, Goodyer C (1996) Amyloid Beta peptide of Alzheimer ’ s disease downregulates Bcl-2 and upregulates Bax expression in human neurons. J Neurosci 16:7533–7539CrossRefGoogle Scholar
  72. Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates. 6th Edition, Academic Press, San DiegoGoogle Scholar
  73. Pazos MR, Núñez E, Benito C, Tolón RM, Romero J (2004) Role of the endocannabinoid system in Alzheimer’s disease: new perspectives. Life Sci 75:1907–1915.  https://doi.org/10.1016/j.lfs.2004.03.026 CrossRefPubMedGoogle Scholar
  74. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 423:435–439.  https://doi.org/10.1038/nature01640 CrossRefPubMedGoogle Scholar
  75. Pilchova I, Klacanova K, Chomova M, Tatarkova Z, Dobrota D, Racay P (2014) Possible contribution of proteins of Bcl-2 family in neuronal death following transient global brain ischemia. Cell Mol Neurobiol 35:23–31.  https://doi.org/10.1007/s10571-014-0104-3 CrossRefPubMedGoogle Scholar
  76. Puighermanal E, Busquets-Garcia A, Maldonado R, Ozaita A (2012) Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc B Biol Sci 367:3254–3263.  https://doi.org/10.1098/rstb.2011.0384 CrossRefGoogle Scholar
  77. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A (2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12:1152–1158.  https://doi.org/10.1038/nn.2369 CrossRefPubMedGoogle Scholar
  78. Rai S, Kamat PK, Nath C, Shukla R (2014) Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav 117:104–117.  https://doi.org/10.1016/j.pbb.2013.11.035 CrossRefPubMedGoogle Scholar
  79. Ramalingam M, Kim S (2014) Insulin involved Akt / ERK and Bcl-2 / Bax pathways against oxidative damages in C6 glial cells. 9893:1–7.  https://doi.org/10.3109/10799893.2014.970276
  80. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904–1913.  https://doi.org/10.1523/JNEUROSCI.4540-04.2005 CrossRefPubMedGoogle Scholar
  81. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E (2008) Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci 28:3051–3059.  https://doi.org/10.1523/JNEUROSCI.5620-07.2008 CrossRefPubMedGoogle Scholar
  82. Ruiz-Valdepeñas L, Benito C, Tolón RM, Martínez Orgado JA, Romero J (2010) The endocannabinoid system and amyloid-related diseases. Exp Neurol 224:66–73.  https://doi.org/10.1016/j.expneurol.2010.03.024 CrossRefPubMedGoogle Scholar
  83. Rutkowska M, Gliniak H (2009) The influence of ACEA: a selective cannabinoid CB1 receptor agonist on whole blood and platelet-poor plasma serotonin concentrations. Pharmazie 64:598–601Google Scholar
  84. Ryu BR, Ko HW, Jou I, Noh JS, Gwag BJ (1999) Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. J Neurobiol 39:536–546.  https://doi.org/10.1002/(SICI)1097-4695(19990615)39:4<536::AID-NEU7>3.0.CO;2-J CrossRefPubMedGoogle Scholar
  85. Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl:217–233.  https://doi.org/10.1007/978-3-211-73574-9-28
  86. Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P (2013) What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research. J Neural Transm 120:233–252.  https://doi.org/10.1007/s00702-012-0877-9 CrossRefPubMedGoogle Scholar
  87. Salkovic-Petrisic M, Osmanovic J, Grünblatt E, Riederer P, Hoyer S (2009) Modeling sporadic Alzheimer’s disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-β. J Alzheimers Dis 18:729–750.  https://doi.org/10.3233/JAD-2009-1184 CrossRefPubMedGoogle Scholar
  88. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96:1005–1015.  https://doi.org/10.1111/j.1471-4159.2005.03637.x CrossRefPubMedGoogle Scholar
  89. Sánchez AJ, García-Merino A (2012) Neuroprotective agents: cannabinoids. Clin Immunol 142:57–67.  https://doi.org/10.1016/j.clim.2011.02.010 CrossRefPubMedGoogle Scholar
  90. Santos TO, Mazucanti CHY, Xavier GF, Torrão AS (2012) Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiol Behav 107:401–413.  https://doi.org/10.1016/j.physbeh.2012.06.019 CrossRefPubMedGoogle Scholar
  91. Sarker KP, Maruyama I (2003) Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci 60:1200–1208.  https://doi.org/10.1007/s00018-003-3055-2 CrossRefPubMedGoogle Scholar
  92. Shen J, Wu Y, Xu JY, Zhang J, Sinclair SH, Yanoff M, Xu G, Li W, Xu GT (2010) ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Investig Ophthalmol Vis Sci 51:35–46.  https://doi.org/10.1167/iovs.09-3544 CrossRefGoogle Scholar
  93. Shoham S, Bejar C, Kovalev E, Schorer-Apelbaum D, Weinstock M (2007) Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 52:836–843.  https://doi.org/10.1016/j.neuropharm.2006.10.005 CrossRefPubMedGoogle Scholar
  94. Song J, Hur BE, Bokara KK, Yang W, Cho HJ, Park KA, Lee WT, Lee KM, Lee JE (2014) Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model. Yonsei Med J 55:689–699.  https://doi.org/10.3349/ymj.2014.55.3.689 CrossRefPubMedPubMedCentralGoogle Scholar
  95. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, De la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? J Alzheimers Dis 7:63–80CrossRefGoogle Scholar
  96. Stygelbout V, Leroy K, Pouillon V, Ando K, D'Amico E, Jia Y, Luo HR, Duyckaerts C, Erneux C, Schurmans S, Brion JP (2014) Inositol trisphosphate 3-kinase B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology. Brain 137:537–552.  https://doi.org/10.1093/brain/awt344 CrossRefPubMedGoogle Scholar
  97. Subramaniam S, Zirrgiebel U, Von Bohlen Und Halbach O, Strelau J, Laliberté C, Kaplan DR, Unsicker K (2004) ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165:357–369.  https://doi.org/10.1083/jcb.200403028 CrossRefPubMedGoogle Scholar
  98. Terranova JP, Storme JJ, Lafon N, Péŕio A, Rinaldi-Carmona M, Le Fur G, Soubrié P (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist R141716. Psychopharmacology 126(2):165–172CrossRefGoogle Scholar
  99. Tsvetanova E, Kessiova M, Alexandrova A, Petrov L, Kirkova M, Todorov S (2006) In vivo effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain of healthy and ethanol-treated rats. Pharmacol Rep 58:876–883PubMedGoogle Scholar
  100. Van Der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V (2006) Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63:1410–1424.  https://doi.org/10.1007/s00018-006-6037-3 CrossRefPubMedGoogle Scholar
  101. Vrechi TA, Crunfli F, Costa AP, Torrão AS (2018) Cannabinoid receptor type 1 agonist ACEA protects neurons from death and attenuates endoplasmic reticulum stress-related apoptotic pathway signaling. Neurotox Res 33.  https://doi.org/10.1007/s12640-017-9839-1
  102. Wei W, Wang X, Kusiak JW (2002) Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 277:17649–17656.  https://doi.org/10.1074/jbc.M111704200 CrossRefPubMedGoogle Scholar
  103. Weksler ME, Gouras G, Relkin NR, Szabo P (2005) The immune system, amyloid-beta peptide, and Alzheimer’s disease. Immunol Rev 205:244–256.  https://doi.org/10.1111/j.0105-2896.2005.00264.x CrossRefPubMedGoogle Scholar
  104. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678–682.  https://doi.org/10.1126/science.1063545 CrossRefPubMedGoogle Scholar
  105. Winter C, Weiss C, Martin-Villalba A, Zimmermann M, Schenkel J (2002) JunB and Bcl-2 overexpression results in protection against cell death of nigral neurons following axotomy. Brain Res Mol Brain Res 104:194–202.  https://doi.org/10.1016/S0169-328X(02)00378-9 CrossRefPubMedGoogle Scholar
  106. Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ (2004) Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci 24:5901–5908.  https://doi.org/10.1523/JNEUROSCI.1346-04.2004 CrossRefPubMedGoogle Scholar
  107. Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH, Choi YH (2014) β-Lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol Ther 22:184–192.  https://doi.org/10.4062/biomolther.2014.026 CrossRefGoogle Scholar
  108. Zhu X, Raina AK, Lee H-G, Chao M, Nunomura A, Tabaton M, Petersen RB, Perry G, Smith MA (2003) Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal 5:571–576.  https://doi.org/10.1089/152308603770310220 CrossRefPubMedGoogle Scholar
  109. Zou S, Kumar U (2018) Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 19.  https://doi.org/10.3390/ijms19030833

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Physiology and Biophysics, Institute of Biomedical SciencesUniversity of São PauloSão PauloBrazil

Personalised recommendations